What Biosensing Instrument does

Biosensing Instrument (legal name: Biosensing Instrument Inc) is a privately held scientific instrumentation company founded in 2003 by Arizona State University researchers and headquartered in Tempe, Arizona. The company designs, manufactures, and sells Surface Plasmon Resonance (SPR) instruments, with a distinctive technological lead in SPR Microscopy (SPRm), a method that combines optical microscopy with SPR to enable label-free, real-time measurement of molecular binding affinity and kinetics directly on whole cells in vitro. Its product portfolio includes the SPRm 220 Series cell-based SPR microscope (launched September 2025), the BI-4500 (5-channel) and BI-2500 (3-channel) benchtop SPR systems, interchangeable analysis modules for flow injection, electrochemical SPR, and gas-phase SPR, a range of proprietary sensor chips and accessories, and a cell-based bioanalytical measurement service for customers who want to outsource SPR experiments.

The company's primary customers are large pharmaceutical companies (Pfizer, AstraZeneca, Genentech, Ferring Pharmaceuticals) conducting drug discovery and membrane protein research, biotech companies focused on biologics development, and academic researchers. Pricing is quote-based with direct sales engagement, multi-year contract terms, and bundled consumables. The go-to-market motion is heavily event-driven: BI exhibits at major drug discovery and biophysics conferences (Discovery on Target, Drug Discovery Chemistry, BPS, NovAliX, AACR) where it offers one-on-one product demonstrations, supplemented by webinars, technical application notes, and direct inbound inquiries through biosensingusa.com.

Biosensing Instrument competes in a global SPR market projected to reach $2.3 billion by 2030 at an 11.5% CAGR. Its differentiation rests on the proprietary SPRm platform (first commercialized in 2017), the BI-DirectFlow module for near-zero-dispersion kinetic measurements, and over 20 years of EC-SPR publication history. The company has been recognized with the 2016 R&D 100 Award for the BI-4500/BI-2500 series and graduated from the Arizona Commerce Authority's Venture Ready Accelerator in 2020. It has no disclosed institutional funding, no public parent company, and operates with a small management team, making it a niche, founder-driven specialist vendor rather than a venture-backed growth company.

Name

Biosensing Instrument

Legal name

Biosensing Instrument Inc

Website

https://biosensingusa.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Biosensing Instrument is a privately held Tempe, Arizona-based manufacturer of Surface Plasmon Resonance (SPR) and SPR Microscopy instruments used by pharmaceutical companies, biotech firms, and academic researchers for label-free molecular binding kinetics and drug discovery applications.

Ownership category

akta.pro rank

Product category

Scientific Instruments - Surface Plasmon Resonance (SPR) Systems

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Proteomics & Mass Spectrometry Services (HLAGANAB)

akta.pro secondary industry

Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)

Keywords

• Surface plasmon resonance
• SPR microscopy instruments
• Label-free binding analysis
• Kinetics measurement systems
• Cell-based bioanalytical tools

Headquarters

HQ city

Tempe

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. SPR Instrumentation Sales: Sale of SPR instruments including SPRm 220 series for cell-based measurements, BI-4500 (5-channel) and BI-2500 (3-channel) benchtop SPR systems. Instruments are sold directly to pharmaceutical companies, biotech companies, and academic researchers.
2. Sensor Chips and Accessories: Sale of various sensor chips (bare gold, divided gold, CM dextran, NI-NTA, streptavidin, Protein A, L1) and accessories including PP-100 automatic buffer exchange pump and BI-Autosampler.
3. Cell-based Bioanalytical Measurement Services: Provides contract measurement services for pharmaceutical companies, biotech companies, and university researchers to measure direct on-cell binding interactions with simultaneous optical imaging. Delivers binding kinetics analysis reports and develops dose response methods.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Biosensing Instrument designs, manufactures, and sells Surface Plasmon Resonance (SPR) and SPR Microscopy (SPRM) instruments used to measure label-free, real-time molecular binding interactions for drug discovery and life science research. Its portfolio includes the SPRm 220 Series cell-based SPR microscopy system, the 5-channel BI-4500, and the 3-channel BI-2500 benchtop SPR systems, complemented by interchangeable Flow Injection, Electrochemical, and Gas Phase analysis modules, sensor chips and accessories, plus contract cell-based bioanalytical measurement services.

Product overview

Biosensing Instrument offers a platform-plus-modules architecture centered on Surface Plasmon Resonance (SPR) technology for label-free molecular interaction analysis. The core product portfolio includes SPRm 220 Series (cell-based SPR microscopy for membrane proteins on whole cells), BI-4500 Series (5-channel high-throughput SPR with BI-DirectFlow), and BI-2500 Series (3-channel SPR for biosensor research). These instruments are complemented by interchangeable analysis modules for Flow Injection SPR, Electrochemical SPR (EC-SPR), and Gas Phase SPR applications. Accessories include various sensor chips (Bare Gold, CM Dextran, NI-NTA, Streptavidin, Protein A, L1), the BI-Autosampler, PP-100 buffer exchange pump, and SPRM Cell Chamber Sensor Kits. The company also provides cell-based bioanalytical measurement services for drug discovery research.

Differentiator

Problem solved

Functional benefit

Brands

• BI-DirectFlow: Flow injection analysis module technology included in BI-4500 series for near-zero dispersion sample delivery
• EC-DualFlow

Products and services

• SPRm 220 Series Cell-based Surface Plasmon Resonance Microscopy system that integrates optical microscopy and SPR for measuring binding affinity and kinetics of membrane proteins on whole cells in vitro, enabling simultaneous analysis of phenotypic changes via brightfield imaging and molecular interactions through SPR. Designed for pharmaceutical, biotech, and academic membrane protein research.
• BI-4500 Series 5-channel SPR instrument with BI-DirectFlow technology for high-throughput assay development, featuring temperature-controlled SPR detection and compatibility with electrochemistry and chemical vapor analysis modules. Used for drug discovery and life science binding kinetics studies.
• BI-2500 Series 3-channel benchtop SPR system preferred for advanced biosensor research including cancer biomarker detection, aptamer development, environmental monitoring, and food contamination analysis, with an open-design architecture supporting integrated electrochemistry and chemical vapor analysis modules.
• Cell-based Bioanalytical Measurement Services Contract cell-based binding assay services that measure direct on-cell binding interactions with simultaneous optical imaging, delivering binding kinetic profiles (KD, kon, koff), dose response methods, and assay optimization for pharmaceutical companies, biotech companies, and university researchers.
• Sensor Chips and Accessories Consumable product line including Bare Gold, Divided Gold, CM Dextran, NI-NTA, Streptavidin, Protein A, and L1 sensor chips for protein immobilization and liposome/vesicle work; the SPRM Cell Chamber Sensor Kit for cell-based SPRM; the BI-Autosampler for automated high-throughput sample delivery; and the PP-100 Automatic Buffer Exchange Pump with Degasser for multi-source buffer handling.

Quantifiable outcome

• Double throughput without compromising data quality with SPRm 220 series
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Arizona State UniversitycoreStrategic or Co-development PartnerCollaboration with Associate Professor Shaopeng Wang from ASU's School of Biological and Health Systems Engineering to commercialize plasmonic imaging technologies for drug discovery and molecular diagnostics applications. The partnership leverages ASU's research expertise with BI's commercialization capabilities.
• Eurofins DiscoverXminorStrategic or Co-development PartnerCollaborative poster presentation at AACR Annual Meeting 2026 on 'Integrated evaluation of payload-, Fc-, and target-mediated mechanisms of ADCs using streamlined complementary platforms'. Demonstrates interoperability of SPRm technology with Eurofins DiscoverX platforms.
• PfizercoreStrategic or Co-development PartnerOngoing collaboration where Pfizer scientists present case studies using SPRm technology. Kris Borzilleri (Principal Scientist) presented on SPR Microscopy measures on-target binding kinetics for integral membrane proteins at NovAliX 2026. Pfizer has conducted multiple webinars and poster presentations showcasing SPRm applications.
• AstraZenecacoreStrategic or Co-development PartnerDr. Niklas Larsson (Associate Principal Scientist) presented on applications of cell-based SPR microscopy at Drug Target Review webinar, showcasing receptor pharmacology studies on GPR39 and target engagement for membrane receptors.
• GenentechcoreStrategic or Co-development PartnerElaine Mai (Senior Scientific Researcher) presented on single cell label-free binding affinity applications, exploring avidities between monovalent and bivalent antibodies in correlation with cellular expression.
• Ferring PharmaceuticalsminorStrategic or Co-development PartnerDr. Marie-Laure Rives (formerly Director Pharmacology at Ferring, now at PostEra) presented on cell-based SPR microscopy application in drug discovery, reviewing case studies of small molecule pH-dependent binding of GPR4.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cytiva (Biacore): Cytiva's Biacore line is the gold-standard SPR instrument platform used across pharma and academic research; it is the primary direct competitor to Biosensing Instrument's BI-2500, BI-4500, and SPRm systems in label-free binding kinetics.
• Reichert Technologies: Reichert offers SPR-based binding analysis instruments and has been a long-standing competitor in the research-grade SPR market, directly comparable to BI's benchtop SPR product family.

Emerging players

• Nicoya Lifesciences: Nicoya is a smaller specialty SPR / biosensor instrument company focused on benchtop, lower-cost label-free interaction analysis; it overlaps with BI's SPR product line, particularly for academic and biotech customers seeking accessible SPR.
• Carterra: Carterra provides high-throughput SPR-based antibody characterization and kinetics platforms; it targets similar pharma/biologics customers as BI with complementary SPR workflows.
• Affinite Instruments: Affinite Instruments builds label-free interaction analysis tools, including SPR-based platforms; it is a smaller emerging player competing for the same drug-discovery and academic research budget as BI.

Broad incumbents

• Malvern Panalytical: Malvern Panalytical offers a broad portfolio of analytical instruments for biomolecular characterization (including MicroCal ITC and related label-free tools); it competes for the same biophysics and drug-discovery budget pool as BI's SPR systems.
• Bruker: Bruker is a large analytical instrumentation provider with products in biophysics and life-science research; while SPR is not its core focus, it competes for the same research-instrument capital budgets as BI in pharma and academic labs.
• Agilent Technologies: Agilent provides a broad portfolio of life-science and analytical instruments used in drug discovery and biopharma research; it is a broad incumbent that competes for the same instrument capital and consumables budgets as BI, though SPR is not its lead product line.
• Horiba Scientific: Horiba Scientific provides spectroscopy and surface analysis instrumentation, including optical sensor platforms relevant to SPR; it serves overlapping pharma, materials, and environmental research customers as BI.

Others

• Eurofins DiscoverX: Eurofins DiscoverX provides cell-based assay platforms for drug discovery and is a documented AACR 2026 collaboration partner of BI; while not an SPR competitor, it represents an adjacent/partner cell-based assay ecosystem relevant to BI's SPRM workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biosensing-instrument-inc
• Xx.com/biosensingins

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosensing Instrument